gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

TRM1 Trm1p

TRM1, Trm1p, TrmI
Sponsored links
Top mentioned proteins: CAN, ACID, Hoxa5, HRs, fibrillin-1
Papers on TRM1
The m1A58 modification in eubacterial tRNA: An overview of tRNA recognition and mechanism of catalysis by TrmI.
New
Tisné et al., Paris, France. In Biophys Chem, Aug 2015
UNASSIGNED: The enzymes of the TrmI family catalyze the formation of the m(1)A58 modification in tRNA.
Substrate tRNA recognition mechanism of eubacterial tRNA (m1A58) methyltransferase (TrmI).
New
Hori et al., Tokyo, Japan. In J Biol Chem, Mar 2015
TrmI generates N(1)-methyladenosine at position 58 (m(1)A58) in tRNA.
Dynamics of RNA modification by a multi-site-specific tRNA methyltransferase.
Golinelli-Pimpaneau et al., Gif-sur-Yvette, France. In Nucleic Acids Res, 2014
In most organisms, the widely conserved 1-methyl-adenosine58 (m1A58) tRNA modification is catalyzed by an S-adenosyl-L-methionine (SAM)-dependent, site-specific enzyme TrmI.
Crystal structure of tRNA m(1)A58 methyltransferase TrmI from Aquifex aeolicus in complex with S-adenosyl-L-methionine.
Yokoyama et al., Yokohama, Japan. In J Struct Funct Genomics, 2014
In thermophilic bacteria, this modification is important for thermal adaptation, and is catalyzed by the tRNA m(1)A58 methyltransferase TrmI, using S-adenosyl-L-methionine (AdoMet) as the methyl donor.
Trm1p, a Zn(II)₂Cys₆-type transcription factor, is essential for the transcriptional activation of genes of methanol utilization pathway, in Pichia pastoris.
Rangarajan et al., Bengaluru, India. In Biochem Biophys Res Commun, 2014
The zinc finger transcription factors Mxr1p and Rop are key regulators of methanol metabolism in the methylotrophic yeast, Pichia pastoris, while Trm1p and Trm2p regulate methanol metabolism in Candida boidinii.
The yeast rapid tRNA decay pathway competes with elongation factor 1A for substrate tRNAs and acts on tRNAs lacking one or more of several modifications.
Phizicky et al., Rochester, United States. In Rna, 2012
We also provide evidence that RTD acts on a variety of tRNAs lacking one or more different modifications, since trm1-Δ trm4-Δ mutants are subject to RTD of tRNA(Ser(CGA)) and tRNA(Ser(UGA)) due to lack of m(2,2)G(26) and m(5)C, and since trm8-Δ, tan1-Δ, and trm1-Δ single mutants are each subject to RTD.
Yeast Trm7 interacts with distinct proteins for critical modifications of the tRNAPhe anticodon loop.
Phizicky et al., Rochester, United States. In Rna, 2012
Further genetic analysis shows that the slow growth of trm7-Δ mutants is due to the lack of both Cm(32) and Nm(34), and the accompanying loss of yW, because trm732-Δ trm734-Δ mutants phenocopy trm7-Δ mutants, whereas each single mutant is healthy; nonetheless, TRM732 and TRM734 each have distinct roles, since mutations in these genes have different genetic interactions with trm1-Δ mutants, which lack m(2,2)G(26) in their tRNAs.
The Arabidopsis TRM1-TON1 interaction reveals a recruitment network common to plant cortical microtubule arrays and eukaryotic centrosomes.
Pastuglia et al., Versailles, France. In Plant Cell, 2012
An archetypal member of this family, TRM1, is a microtubule-associated protein that localizes to cortical microtubules and binds microtubules in vitro.
(99m)Tc-Labeled lexatumumab
Review
Chopra, Bethesda, United States. In Unknown Journal, 2009
A similar mAb, mapatumumab (TRM-1 or HGS-ETR1), is a TRAIL-R1 mAb that acts as an agonist specifically for the TRAIL-R1 and has been approved by the USFDA for clinical trials.
(111)In-Labeled lexatumumab
Review
Chopra, Bethesda, United States. In Unknown Journal, 2009
A similar mAb, mapatumumab (TRM-1 or HGS-ETR1), is a TRAIL-R2 mAb that acts as an agonist specifically for the TRAIL-R2 and has been approved by the USFDA for clinical trials.
(111)In-Labeled mapatumumab
Review
Chopra, Bethesda, United States. In Unknown Journal, 2009
Mapatumumab (TRM-1 or HGS-ETR1) is a TRAIL-R1 monoclonal Ab (mAb) that targets TRAIL-R1; it is under commercial development and has been approved for clinical trials by the United States Food and Drug Administration (USFDA) to treat various cancers.
(99m)Tc-Labeled mapatumumab
Review
Chopra, Bethesda, United States. In Unknown Journal, 2009
Mapatumumab (TRM-1 or HGS-ETR1) is a TRAIL-R1 monoclonal antibody (mAb) that targets TRAIL-R1; it is under commercial development and has been approved for clinical trials by the United States Food and Drug Administration (USFDA) to treat various cancers.
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
Impact
Cohen et al., San Antonio, United States. In J Clin Oncol, 2007
PURPOSE: To assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal antibody directed to the tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1).
How single genes provide tRNA processing enzymes to mitochondria, nuclei and the cytosol.
Review
Hopper et al., Louisville, United States. In Biochimie, 1993
The product of the TRM1 gene is N2,N2 dimethylguanosine tRNA methyltransferase.
Defects in modification of cytoplasmic and mitochondrial transfer RNAs are caused by single nuclear mutations.
Impact
Martin et al., In Cell, 1982
These studies utilize two yeast genes: TRM1 and TRM2.
share on facebooktweetadd +1mail to friends